alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › treated

treated

5 studies tagged treated, dated 2025-06-04 to 2026-08-13. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Baseline Amyloid PET Centiloid Score and Risk of Amyloid-Related Imaging Abnormalities in Patients Treated With Lecanemab 2026-08-13
  2. Demographic and Clinical Characteristics of Patients Treated With Lecanemab Stratified by Amyloid-Related Imaging Abnormality Status 2026-08-13
  3. Reduced diffusion associated with amyloid-related imaging abnormalities in three patients treated with donanemab 2026-07-02

Studies

5 studies carry this tag.

Date range

2025 to 2026

Top journals

  • Neurocase 2
  • AJNR. American journal of neuroradiology 1
  • Cureus 1
  • Current opinion in neurology 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Baseline Amyloid PET Centiloid Score and Risk of Amyloid-Related Imaging Abnormalities in Patients Treated With Lecanemab

    ✓ Peer-reviewed alzhub usefulness score 50 out of 100. AJNR. American journal of neuroradiology 2026-08-13 Treatments

    Baseline global Centiloid was not independently associated with ARIA in patients treated with lecanemab.

  2. Demographic and Clinical Characteristics of Patients Treated With Lecanemab Stratified by Amyloid-Related Imaging Abnormality Status

    ✓ Peer-reviewed alzhub usefulness score 66 out of 100. Cureus 2026-08-13 Treatments

    In this real-world cohort of patients treated with lecanemab, ARIAs occurred in nearly one-third of patients.

  3. Reduced diffusion associated with amyloid-related imaging abnormalities in three patients treated with donanemab

    ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Neurocase 2026-07-02 Treatments

    Amyloid-related imaging abnormalities (ARIA) with edema (ARIA-E) and with hemorrhage (ARIA-H) are common adverse effects of amyloid-targeting therapies (ATT), characterized on MRI by T2/fluid-attenuated inversion recovery (FLAIR) hyperintensities and susceptibility-sensitive hypointensities, respectively.

  4. Multiple ischemic strokes in a patient treated with Lecanemab: a case report

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Neurocase 2025-10-16 Treatments

    Amyloid-lowering therapy via administration of monoclonal antibodies against amyloid beta has been previously associated with the formation of cerebral edema and/or microhemorrhage.

  5. MRI protocols and sequences for amyloid-related imaging abnormalities monitoring in Alzheimer's disease patients treated with monoclonal antibodies

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Current opinion in neurology 2025-06-04 Treatments

    This review provides an updated overview of amyloid-related imaging abnormalities (ARIA) associated with antiamyloid monoclonal antibodies (mAbs) in Alzheimer's disease (AD).

All topic tags with their study counts